As companies face the task of determining how to best bring some employees back to the workplace, here are five PR strategies to keep in mind when communicating. https://t.co/EyZyIRfgot
#WorkFromHome#WFH#PublicRelations
A press release goes beyond publication. Keep up with the visibility and results of your press release after distributing it to maximize the press release’s potential. #ACCESSNewswire#PressReleaseDistribution#PRStrategy
Seven AI agents. One SPOT-on press release. 🎯
With SPOT, you can clearly identify opportunities to strengthen your press release while there’s still time to act. See it in action: https://t.co/6KROPZ7ULA.
#PublicRelations#PressReleases#PRStrategy#AIinPR#SeeSPOTWork
Four words no PR pro wants to say: “We should’ve caught that.”
From readability to AI visibility, SPOT helps you spot opportunities to strengthen your release before hitting submit.
Discover SPOT: https://t.co/6KROPZ7ULA
#PublicRelations#PRTech#AIinPR
News discovery is changing. Introducing SPOT, ACCESS Newswire’s new suite of seven AI agents designed to help PR and IR teams make smarter publishing decisions.
SPOT it before you submit it: https://t.co/6KROPZ7ULA
#SPOTByAccess#PublicRelations#AI
Aytu BioPharma (@AytuBioPharma_) to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
https://t.co/gjD6rQBxI7
Petros Pharmaceuticals (@PetrosPharma) Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
https://t.co/dNzfIdGlCo
Full Alliance Group, Inc. (@OTCFAGI) (OTC: FAGI) Wholly Owned Subsidiary Dynamaxx Health Inc. Secures Its Own Manufacturing Contract for Medical Devices for MAXX Health Clinics
https://t.co/9ygNKSeig3
FSD Pharma (@FsdPharma) Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
https://t.co/2G5v8hk0yd
Petros Pharmaceuticals' (@PetrosPharma) Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
https://t.co/wJdvJwboVc